Processing

Please wait...

Settings

Settings

Goto Application

1. WO2016134416 - A METHOD FOR ASSESSING PROGNOSIS OF LYMPHOMA

Publication Number WO/2016/134416
Publication Date 01.09.2016
International Application No. PCT/AU2016/050118
International Filing Date 23.02.2016
IPC
C12Q 1/68 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
CPC
C12Q 1/68
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
C12Q 2600/118
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
118Prognosis of disease development
C12Q 2600/158
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS
2600Oligonucleotides characterized by their use
158Expression markers
Applicants
  • THE UNIVERSITY OF QUEENSLAND [AU]/[AU]
Inventors
  • GANDHI, Maher
  • KEANE, Colm Gerard
  • LE CAO, Kim-Anh
  • VARI, Francesco
Agents
  • FPA PATENT ATTORNEYS PTY LTD
Priority Data
201590062523.02.2015AU
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) A METHOD FOR ASSESSING PROGNOSIS OF LYMPHOMA
(FR) MÉTHODE D'ÉVALUATION DU PRONOSTIC D'UN LYMPHOME
Abstract
(EN)
The invention relates to methods, devices and kits for providing prognosis of subjects having lymphoma. In particular, the methods relate to determining likelihood of survival, recurrence or treatment outcome in B-cell lymphoma patients who have undergone and/or undergoing chemotherapy. In particular, the present invention provides a method for providing a prognosis of a subject having diffuse large B-cell lymphoma responding to a treatment regime including an anthracycline and a B-celldepleting antibody, such as an anti-CD20 antibody, the method comprising: determining an immune score for the subject based upon the ratio of a level of any one or more of CD137, CD4, CD8, CD56, TNFα (alpha) and LMO2 in the subject to a level of any one or more of PD-1, PD-L1, CD163, CD68, PD-L2, LAG3, TIM3 and SCYA3(CCL3) in the subject, comparing the immune score to a reference score; wherein the immune score in comparison with the reference score is indicative of the subject's prognosis of responding to a treatment regime including an anthracycline and a B-cell depleting antibody.
(FR)
L'invention concerne des méthodes, des dispositifs et des kits permettant d'obtenir le pronostic de sujets atteints d'un lymphome. En particulier, lesdites méthodes consistent à déterminer la probabilité de survie, la récurrence ou l'issue d'un traitement chez des patients atteints d'un lymphome d'immunotype B qui suivent et/ou qui ont suivi une chimiothérapie. En particulier, la présente invention concerne une méthode permettant d'obtenir un pronostic d'un sujet atteint d'un lymphome diffus à grandes cellules d'immunotype B répondant à un schéma thérapeutique comprenant une anthracycline et un anticorps appauvri en lymphocytes B, tel qu'un anticorps anti-CD20, ladite méthode consistant à : déterminer un score immunitaire pour le sujet sur la base du rapport d'un taux d'un ou plusieurs éléments quelconques parmi CD137, CD4, CD8, CD56, TNFα (alpha) et LMO2 chez le sujet à un taux d'un ou plusieurs éléments quelconques parmi PD-1, PD-L1, CD163, CD68, PD-L2, LAG3, TIM3 et SCYA3 (CCL3) chez le sujet, et comparer le score immunitaire à un score de référence; le score immunitaire en comparaison avec le score de référence indiquant le pronostic du sujet à répondre à un schéma thérapeutique comprenant une anthracycline et un anticorps appauvri en lymphocytes B.
Latest bibliographic data on file with the International Bureau